The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions

Immunohistochemical staining for FHIT and PCNA proteins was carried out in 451 breast lesions showing nonproliferative benign breast disease (BBD) (n=263), proliferative BBD without atypia (n=128), proliferative BBD with atypia (n=11), carcinoma in situ (n=15) or invasive carcinoma (n=34) and for EGFR protein in a subset of 71 of these cases. FHIT underexpression was not detected in nonproliferative lesions, but occurred in 2% of proliferative BBD without atypia, 10% proliferative BBD with atypia, 27% of carcinoma in situ and 41% of invasive carcinoma, which suggests that it could be useful in assessing those carcinoma in situ lesions (ductal, DCIS and lobular, LCIS) that are more likely to progress to malignancy. Preliminary microarray comparisons on DCIS and invasive carcinoma samples dissected from formalin-fixed paraffin sections showed a consistent downregulation of two previously identified FHIT-related genes, caspase 1 and BRCA1 in lesions underexpressing FHIT.

• Publication year

  2006

• Venue

  British Journal of Cancer

• Publication date

  2006-12-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.bjc.6603512PMID 17164758PMCID 2360209
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A molecular correlate to the Gleason grading system for prostate adenocarcinoma.

  2006cited by this paper
• Loss of FHIT Expression in Breast Cancer Is Correlated with Poor Prognostic Markers

  2005cited by this paper
• EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

  2005cited by this paper
• Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.

  2005cited by this paper
• Loss of caspase-1 gene expression in human gastric carcinomas and cell lines.

  2005cited by this paper
• EGFR gene copy number heterogeneity in fine‐needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization

  2005cited by this paper
• Fhit and CHK1 have opposing effects on homologous recombination repair.

  2005cited by this paper
• Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil

  2004cited by this paper
• The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression

  2004cited by this paper
• Synergistic Tumor Suppression by Coexpression of FHIT and p53 Coincides with FHIT-Mediated MDM2 Inactivation and p53 Stabilization in Human Non-Small Cell Lung Cancer Cells

  2004cited by this paper
• FHIT protein expression and its relation to apoptosis, tumor histologic grade and prognosis in colorectal adenocarcinoma: An immunohistochemical and image analysis study

  2004cited by this paper
• Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.

  2004influential reference
• Fhit is a physiological target of the protein kinase Src.

  2004cited by this paper
• Ubc9-induced inhibition of diadenosine triphosphate hydrolase activity of the putative tumor suppressor protein Fhit.

  2004influential reference
• The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions

  2004cited by this paper
• Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer

  2003cited by this paper
• EGFR, HER-2/neu, Cyclin D1, p21 and p53 in Correlation to Cell Proliferation and Steroid Hormone Receptor Status in Ductal Carcinoma in situ of the Breast

  2003cited by this paper
• Gene expression profiles of human breast cancer progression

  2003cited by this paper
• The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.

  2002cited by this paper
• A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.

  2002cited by this paper
• FHIT: from gene discovery to cancer treatment and prevention.

  2002cited by this paper
• Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines

  2002cited by this paper
• Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.

  2001cited by this paper
• Human Prostate Cancer Loss of Caspase-1 and Caspase-3 Protein Expression in Updated Version

  2001cited by this paper
• Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma.

  2001influential reference
• High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss.

  2001influential reference
• Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer.

  2001cited by this paper
• Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.

  2001cited by this paper
• HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer.

  2000influential reference
• Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9.

  2000influential reference
• Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology.

  2000cited by this paper
• The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma

  2000cited by this paper
• Historical and Epidemiologic Background of Human Premalignant Breast Disease

  2000influential reference
• Interleukin 1 and interleukin 1β converting enzyme (caspase 1) expression in the human colonic epithelial barrier. Caspase 1 downregulation in colon cancer

  1999cited by this paper
• Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

  1999cited by this paper
• FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease.

  1999cited by this paper
• Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype.

  1998cited by this paper
• An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non‐familial breast cancers

  1998cited by this paper
• Benign breast diseases and premalignant breast disease.

  1998influential reference
• Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix

  1995cited by this paper
• Comparative flow cytometric analysis of Ki-67 and proliferating cell nuclear antigen (PCNA) in solid neoplasms.

  1994cited by this paper
• Segregation analysis of breast cancer: histopathologic data.

  1991cited by this paper

• Epidermal Growth Factor Receptor and its Oncogenic EGFRvIII Variant in Benign and Malignant Brain Tumors

  2021cites this paper
• P53, HER2/neu, Bcl-2 and PCNA overexpression in ductal carcinoma in situ lesions of the breast and their role in progression to invasive carcinoma

  2019cites this paper
• Karsinoma in Situ Lezyonları : Histopatolojik özellikler ile p 53 , HER 2 / neu , bcl-2 ve PCNA Ekspresyonu arasındaki ilişki

  2018influential citation
• Fhit down-regulation is an early event in pancreatic carcinogenesis

  2017cites this paper
• Basal Cell Adenocarcinoma and Basal Cell Adenoma of the Salivary Glands: A Clinicopathological Review of Seventy Tumors with Comparison of Morphologic Features and Growth Control Indices

  2015cites this paper
• Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients

  2015cites this paper
• Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.

  2015cites this paper
• Helping the hypermutator: The Fhit-APOBEC connection

  2015cites this paper
• Computational Survey of FHIT, A Putative Human Tumor Suppressor, Truncates Structure

  2014cites this paper
• FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis

  2014cites this paper
• Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer

  2013cites this paper
• Differential loss of heterozygosity profile on chromosome 3p in ductal and lobular breast carcinomas.

  2012cites this paper
• Ginsenoside Rh2 induces Bcl‐2 family proteins‐mediated apoptosis in vitro and in xenografts in vivo models

  2011cites this paper
• Pathology and biology associated with the fragile FHIT gene and gene product

  2010influential citation
• FIBROADENOMAS MAMÁRIOS HUMANOS: EPIDEMIOLOGIA E ANÁLISE DA PERDA DE HETEROZIGOSE NA REGIÃO 3p

  2009cites this paper
• Coordinate Loss of Fragile Gene Expression in Pancreatobiliary Cancers: Correlations Among Markers and Clinical Features

  2009cites this paper
• Withaferin A Causes FOXO 3 aand Bim-Dependent Apoptosis and Inhibits Growth of Human Breast Cancer Cells In Vivo

  2008cites this paper
• Specific 5′CpG Island Methylation Signatures of FHIT and p16 Genes and Their Potential Diagnostic Relevance in Indian Breast Cancer Patients

  2008cites this paper
• Identification of estrogen‐responsive proteins in MCF‐7 human breast cancer cells using label‐free quantitative proteomics

  2008cites this paper
• Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo.

  2008cites this paper